Form 8-K - Current report:
SEC Accession No. 0001714899-21-000113
Filing Date
2021-11-17
Accepted
2021-11-17 09:03:27
Documents
14
Period of Report
2021-11-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20211117.htm   iXBRL 8-K 40245
2 EX-99.1 ex991pressrelease11172021.htm EX-99.1 19473
6 denali_txlogox02a.jpg GRAPHIC 680367
  Complete submission text file 0001714899-21-000113.txt   1130987

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20211117.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20211117_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20211117_pre.xml EX-101.PRE 12528
7 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20211117_htm.xml XML 10900
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 211418570
SIC: 2836 Biological Products, (No Diagnostic Substances)